In a regulatory submitting, Zydus Cadila mentioned “it has successfully completed a phase 2 clinical trial in Covid-19 patients with its biological therapy, Pegylated Interferon alpha-2b, ‘PegiHep’… Based upon the results from its Phase 2 study, Zydus Cadila now plans to conduct a phase 3 clinical trial in India”.
Zydus Cadila, which is part of the Cadila Healthcare group, mentioned Pegylated Interferon alpha 2b considerably elevated viral discount and lowered the necessity for supplemental oxygen in average Covid-19 sufferers.
“We continue to look at possible treatment options that are safe and efficacious in the treatment and management of Covid-19. Pegylated Interferon alpha-2b has shown the potential to reduce virus titres when given earlier in the disease and we will like to explore this biological option further. We are hopeful of reinforcing our treatment options to fight Covid-19,” Sharvil Patel, Managing Director, Cadila Healthcare Ltd mentioned.
Pegylated Interferon alpha-2b will not be a brand new remedy. The product was first accredited internationally in 2001 and can also be included in WHO’s Essential Medicines List.
Zydus Cadila mentioned its Pegylated Interferon alpha-2b, PegiHep, was initially accredited for Hepatitis C and was launched within the Indian market in 2011.
Since then secure and efficacious drug use for this product has been demonstrated in 1000’s of sufferers, the corporate added.
Zydus Cadila mentioned it had performed this research on the approval from the Drugs Controller General of India (DCGI) to research the position of Pegylated Interferon alpha-2b for Covid-19. The firm can also be conducting the same section 2 trial in Mexico.
The firm can also be working with the US Food and Drug Administration (USFDA) to open an Investigational New Drug (IND) software for Pegylated Interferon alpha-2b as a way to provoke applicable medical trials within the US.